THALOMID
LOE ApproachingNDAORALCAPSULE
Approved
May 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
THALOMID by Bristol Myers Squibb is understood. First approved in 2006.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THALOMID (thalidomide) is an oral immunomodulatory agent approved in 2006 for treatment of multiple myeloma. The drug works by binding to cereblon, a component of E3 ubiquitin ligase complexes, thereby modulating immune function and inhibiting angiogenesis. THALOMID suppresses TNF-α production, enhances natural killer cell activity, and blocks endothelial cell proliferation, making it a foundational agent in myeloma combination therapy regimens.
$0.0BPart D
Mechanism of Action
understood. Cellular activities of thalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. THALOMID possesses immunomodulatory, anti-inflammatory and antiangiogenic properties. Available data from in vitro studies and clinical trials…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on THALOMID at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.